The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carboplatin beyond 4 cycles during therapy with carboplatin, pemetrexed, and pembrolizumab for advanced non-small cell lung cancer (NSCLC).
 
Yaser Ahmad
No Relationships to Disclose
 
Dung-Tsa Chen
No Relationships to Disclose
 
Jhanelle Elaine Gray
Honoraria - Jazz Pharmaceuticals; Merck; OncoCyte
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol Myers Squibb; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Lilly; Loxo; Merck Sharp & Dohme; National Comprehensive Cancer Network; Novartis; Sanofi
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); ECOG-ACRIN (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); SWOG (Inst)
Travel, Accommodations, Expenses - Novartis; OncoCyte
 
Tawee Tanvetyanon
No Relationships to Disclose